📊 PTPI Key Takeaways
Is Petros Pharmaceuticals, Inc. (PTPI) a Good Investment?
Petros Pharmaceuticals exhibits severe operational distress with -$5.8M operating cash flow against only $203.7K in revenue, indicating an unsustainable business model. Positive net income appears driven by non-operating items rather than core operations, while cash burn at current rates provides only ~1 year of runway. Fundamental viability is highly questionable for a pharmaceutical company with negligible revenue and persistent operational losses.
Petros Pharmaceuticals, Inc. Key Strengths (PTPI)
- Strong liquidity position with 2.22x current ratio and adequate cash reserves of $6.1M
- Moderate debt levels with 0.52x debt-to-equity ratio and manageable leverage
- Exceptional revenue growth rate of 1275% YoY, though from negligible base
PTPI Stock Risks: Petros Pharmaceuticals, Inc. Investment Risks
- Critical cash burn: -$5.8M operating cash flow against $6.1M total cash provides ~1 year runway at current rates
- Severe operational losses of -$4.2M on $203.7K revenue with -2086.8% operating margin indicating non-viable business model
- Profitability metrics appear distorted by non-operating gains; negative EPS contradicts positive net income, suggesting earnings quality issues and potential accounting irregularities
- Negligible revenue base insufficient to support pharmaceutical R&D and operations; likely shell company or pre-revenue biotech
- No insider buying activity in 90 days suggests lack of management confidence
Key Metrics to Watch
- Operating cash flow trend - company must achieve cash flow break-even before reserves deplete
- Revenue trajectory - current base of $203.7K is insufficient; must scale significantly or shut down
- Cash burn rate and remaining runway - critical survival metric given operational losses
Petros Pharmaceuticals, Inc. (PTPI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.22x current ratio provides a solid financial cushion.
PTPI Profit Margin, ROE & Profitability Analysis
PTPI vs Healthcare Sector: How Petros Pharmaceuticals, Inc. Compares
How Petros Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Petros Pharmaceuticals, Inc. Stock Overvalued? PTPI Valuation Analysis 2026
Based on fundamental analysis, Petros Pharmaceuticals, Inc. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Petros Pharmaceuticals, Inc. Balance Sheet: PTPI Debt, Cash & Liquidity
PTPI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Petros Pharmaceuticals, Inc.'s revenue has declined by 39% over the 5-year period, indicating business contraction. The most recent EPS of $-83.47 indicates the company is currently unprofitable.
PTPI Revenue Growth, EPS Growth & YoY Performance
PTPI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $1.6M | -$2.2M | $-0.53 |
| Q2 2024 | $1.4M | -$662.0K | $-0.37 |
| Q1 2024 | $1.4M | -$1.4M | $-0.66 |
| Q2 2023 | $2.0M | -$1.8M | $-0.88 |
| Q1 2023 | $2.5M | -$174.2K | $-0.08 |
| Q3 2022 | $2.1M | -$800.7K | $-0.08 |
| Q2 2022 | $2.5M | $896.2K | $0.09 |
| Q1 2022 | $2.5M | -$174.2K | $-0.01 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Petros Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
PTPI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Petros Pharmaceuticals, Inc. (CIK: 0001815903)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PTPI
What is the AI rating for PTPI?
Petros Pharmaceuticals, Inc. (PTPI) has an AI grade of D with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PTPI's key strengths?
Claude: Strong liquidity position with 2.22x current ratio and adequate cash reserves of $6.1M. Moderate debt levels with 0.52x debt-to-equity ratio and manageable leverage.
What are the risks of investing in PTPI?
Claude: Critical cash burn: -$5.8M operating cash flow against $6.1M total cash provides ~1 year runway at current rates. Severe operational losses of -$4.2M on $203.7K revenue with -2086.8% operating margin indicating non-viable business model.
What is PTPI's revenue and growth?
Petros Pharmaceuticals, Inc. reported revenue of $203.7K.
Does PTPI pay dividends?
Petros Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find PTPI SEC filings?
Official SEC filings for Petros Pharmaceuticals, Inc. (CIK: 0001815903) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PTPI's EPS?
Petros Pharmaceuticals, Inc. has a diluted EPS of $-1.95.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PTPI's fundamental grade?
Based on our AI fundamental analysis in June 2026, Petros Pharmaceuticals, Inc. has a D grade with 78% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is PTPI stock overvalued or undervalued?
Valuation metrics for PTPI: ROE of 66.8% (sector avg: 15%), net margin of 1,104.9% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
What is PTPI's AI grade for 2026?
Our dual AI analysis gives Petros Pharmaceuticals, Inc. a combined D grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is PTPI's free cash flow?
Petros Pharmaceuticals, Inc.'s operating cash flow is $-5.8M, with capital expenditures of $24.6K. FCF margin is -2,860.6%.
How does PTPI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 1,104.9% (avg: 12%), ROE 66.8% (avg: 15%), current ratio 2.22 (avg: 2).
Why is PTPI's return on equity (ROE) so high?
Petros Pharmaceuticals, Inc. has a return on equity of 66.8%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity. This is supported by a 1,104.9% net margin.